Effects of combination lipid therapy in type 2 diabetes mellitus. - Wikidata - awgldk - TriplyDB

Effects of combination lipid therapy in type 2 diabetes mellitus.

Effects of combination lipid therapy in type 2 diabetes mellitus.

http://www.wikidata.org/entity/Q33889260

about

Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Summary Fibrates for secondary prevention of cardiovascular disease and stroke Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus Fibrates for primary prevention of cardiovascular disease events Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline Opening a new lipid "apo-thecary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk Standards of medical care in diabetes--2012 Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease High density lipoprotein and metabolic disease: Potential benefits of restoring its functional properties Diabetes Dyslipidemia Hypertriglyceridemia and Cardiovascular Diseases: Revisited Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction Dyslipidemia management in primary prevention of cardiovascular disease: Current guidelines and strategies Use of fibrates in the metabolic syndrome: A review PPARs: Protectors or Opponents of Myocardial Function?Interaction between Glucose and Lipid Metabolism: More than Diabetic Dyslipidemia HDL/ApoA-1 infusion and ApoA-1 gene therapy in atherosclerosis PCSK9 inhibition: the way forward in the treatment of dyslipidemia Origin and therapy for hypertriglyceridaemia in type 2 diabetes Cardiovascular risk Lipid-lowering therapy: who can benefit?Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects Dyslipidemia and its therapeutic challenges in renal transplantation Benefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians - a population with the highest risk of premature coronary artery disease & diabetes New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications--a review Residual macrovascular risk in 2013: what have we learned?Applications of mass spectrometry for cellular lipid analysis Role of lipotoxicity in endothelial dysfunction Statins in cardiometabolic disease: what makes pitavastatin different?Lipid-lowering agents in the management of nonalcoholic fatty liver disease Lipid abnormalities in kidney disease and management strategies Treatment of dyslipidemia Calcium and phosphate impact cardiovascular risk.Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association.Diagnosis and treatment of high density lipoprotein deficiency New Era of Lipid-Lowering Drugs

P2860

Q21246041-AA4E4806-0F9D-4FD3-8E6D-53658AC57443 Q22241786-57176E89-C94D-4D38-B1BE-6E1D7CF792EB Q24186376-C9D2D349-4F75-4950-BB84-15F1944241E2 Q24186667-206C6E16-C07A-44E9-9E66-856C9AB3052B Q24202505-E5B70274-CB14-472D-89AD-A61A4378138E Q24203618-EA327593-B193-4E54-94C2-3D5BBACCED82 Q24236456-47441AA1-C611-408B-B4D8-F43EB639E28E Q24608464-9A1F27F3-12A5-42AD-AAFD-531793CF1FE3 Q24626884-6834E5F2-2BED-4D0E-89F4-1DC37A7A8F51 Q24632533-E179367F-76C9-4CAC-96C2-D445B41ABD8A Q26745946-CD2B1C8A-8CE3-4B1B-A627-0F013ACD367C Q26750603-E5C52FC9-B73F-4B00-B3B0-783CD461F31E Q26750905-F2E7272A-D44A-4D96-A1C1-D810A09B1505 Q26750954-45497513-4F79-4012-B13C-1702CCA2EA8D Q26752950-A0FE1B0C-066E-466D-A70B-236282E18BB2 Q26765157-717F3383-4304-4246-872F-F5A22D6D771B Q26765234-C4CF867C-2BFD-4EA6-AB46-7ABCF1D3D6FF Q26771753-11F26C98-5D59-4CAA-97BC-FC0452A2C0F0 Q26777184-B08CA380-0EF0-4677-8973-122AF1D5DD58 Q26782972-E2578898-1FCA-4654-82B7-CD733B17B821 Q26784482-C282F87D-F330-4157-9E8D-2201D7645973 Q26824004-56ED6091-B0CD-4992-8384-03A1DFF9771D Q26825634-DA30F1CD-ACE3-4EB5-9F58-BB3FC3F8EFD6 Q26827432-0B7EA598-ED53-4B38-BAB1-DA289A8C5E5D Q26829098-D779E411-8F84-4F21-828B-8140C7CCD82E Q26851294-4B60FEC5-4AF5-4F38-B1F8-BB64DE3B43AD Q26853571-3FC3F6C6-A072-4EB0-873A-D73CDCAA8C7D Q26863369-4C010B86-06FC-4921-9850-C7058A39C998 Q26866784-45439964-BA7F-450C-8A31-87A48ECFEEF9 Q26996039-964CE508-B341-4B73-AFE0-EDF078DF9ACA Q26996187-32EC3189-815B-4CC3-8F69-3717227251E6 Q27000731-D7BC995E-19F7-4EF4-9FD3-A9C3AACE7D5D Q27010638-3E891B4C-386A-4FD6-88AC-43653DD53EBE Q27024352-0A1E183B-F709-45E9-96BE-CF83DAEEA232 Q27024982-A9204A34-1A4C-4E0F-A6B2-C7ABC7771819 Q27026114-EFCAB329-1820-4E79-9674-4367ABFFF4A4 Q27687570-C45252E9-E080-484E-9F50-9CBED8F420F6 Q27687851-A2A3C9AB-8AC1-4D0E-89CD-06930CC0FD41 Q28067479-3830D42C-0EBD-4278-846A-9140399A539E Q28072298-43A5B06B-A544-408E-93A9-0A7B42ADC155

P2860

Effects of combination lipid therapy in type 2 diabetes mellitus.

http://www.wikidata.org/entity/Q33889260

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Effects of combination lipid therapy in type 2 diabetes mellitus.

@ast

Effects of combination lipid therapy in type 2 diabetes mellitus.

@en

type

label

Effects of combination lipid therapy in type 2 diabetes mellitus.

@ast

Effects of combination lipid therapy in type 2 diabetes mellitus.

@en

prefLabel

Effects of combination lipid therapy in type 2 diabetes mellitus.

@ast

Effects of combination lipid therapy in type 2 diabetes mellitus.

@en

P1433

Q33889260-7C6E3C71-D9CD-41C4-B5DF-22D79EEA462A

P1476

Q33889260-94B36723-53BA-4700-B0A5-129D84B34B27

P2093

Q33889260-39A74A3D-030D-4DEE-B82A-518F1EADACF7

Q33889260-4AFD7B9F-FEE5-41D2-9AFB-C478F109DF2F

Q33889260-5338B6F3-E6DE-42CD-8C80-76C04131CB10

Q33889260-54BDFF63-23EB-42DC-A1E5-A2F57FE3B467

Q33889260-5568FA73-C82A-4E84-8B2F-593D49731E1E

Q33889260-5A3B860F-B12F-4B7E-B8D5-1E7447EBE71D

Q33889260-849AA54B-38CF-4CB1-8357-471098DD504F

Q33889260-84E839B1-C760-4B8A-9720-FBD18CB88700

Q33889260-9CADC438-44F1-4246-B835-AEACF5099EB3

Q33889260-AE94E2F8-C19F-424B-96EA-E5EAFEEDDC88

P2860

Q33889260-010817C7-1FE5-4138-BE88-D4EC9408C924

Q33889260-157058B5-574D-4B4E-AB48-F1F244B8C05A

Q33889260-21BD5805-BBA9-43EF-A356-41F2C46851ED

Q33889260-238B758A-3F81-44C7-AAD8-ADECF0EE278E

Q33889260-35ACBB55-A0B2-497B-A952-497E28151D9D

Q33889260-41FC1A16-0634-4A7F-8F9E-E5352239C223

Q33889260-4EF8A2E6-6606-447A-BA0F-26C95B3B679F

Q33889260-53499A63-D794-456D-9992-35B80EE5DD0E

Q33889260-5B10A64C-00FA-4EBA-AAD5-FB4DC5BB298C

Q33889260-5E756F1E-F5E5-4862-8392-A67B9EAF7DA4

P304

Q33889260-101F073B-ECFC-4E84-B639-EE0D0A4F9161

P31

Q33889260-744A0718-F6CA-43C0-9B3B-7A67B37CA0FF

P356

Q33889260-E77707DC-5ECA-4632-859A-6F4977B33178

P407

Q33889260-EB50D2B7-455A-475D-B6AD-EFDAF6807978

P433

Q33889260-DA1B219D-30AA-4C9C-88FA-0108A9DF52CA

P478

Q33889260-CA924878-F35A-4EFD-89B9-64E77FA2ABF6

P50

Q33889260-2F99D8D5-DCCC-41AF-976A-DC3D57D9AB5F

Q33889260-5C74369B-389C-451C-808B-3669CA322148

P577

Q33889260-9EB889C0-B6E7-48CA-B687-607A1FCFC4ED

P698

Q33889260-377BE2DD-3F42-4781-976B-C98BDE23A940

P921

Q33889260-AC8E5479-700A-4FD9-A84C-D42BF46AF0AE

P932

Q33889260-C7B85198-70F2-44CC-B628-0C225DC56758

P356

P1433

The New England Journal of Medicine

P1476

Effects of combination lipid therapy in type 2 diabetes mellitus.

@en

P2093

ACCORD Study Group

http://www.w3.org/2001/XMLSchema#string

David C Goff

http://www.w3.org/2001/XMLSchema#string

Denise G Simons-Morton

http://www.w3.org/2001/XMLSchema#string

Faramarz Ismail-Beigi

http://www.w3.org/2001/XMLSchema#string

Henry N Ginsberg

http://www.w3.org/2001/XMLSchema#string

J Thomas Bigger

http://www.w3.org/2001/XMLSchema#string

Jeffrey Probstfield

http://www.w3.org/2001/XMLSchema#string

John R Crouse

http://www.w3.org/2001/XMLSchema#string

Laura C Lovato

http://www.w3.org/2001/XMLSchema#string

Lawrence A Leiter

http://www.w3.org/2001/XMLSchema#string

P2860

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

Effects of intensive glucose lowering in type 2 diabetes

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)

P304

1563-1574

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1001282

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

362

http://www.w3.org/2001/XMLSchema#string

P50

Hertzel C. Gerstein

P577

2010-03-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20228404

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

2879499

http://www.w3.org/2001/XMLSchema#string